NasdaqGS:RVMDBiotechs
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst
Revolution Medicines (RVMD) recently announced that nine presentations covering clinical and preclinical data from its RAS(ON) inhibitor pipeline will be featured at the 2026 AACR Annual Meeting in San Diego.
See our latest analysis for Revolution Medicines.
The recent AACR news comes after a 21.6% 90 day share price return and a very large 3 year total shareholder return, suggesting momentum has been building around Revolution Medicines' RAS(ON) program despite short term share price...